This video reviews new studies examining the genetic drivers of three rare genitourinary cancers: von Hippel-Lindau disease, advanced papillary renal cell carcinoma, and penile cancer.
Guru Sonpavde, MD
Since the development of first-line cisplatin-based combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin almost 3 decades ago, there have not been major advances in the treatment of this disease.
Occult distant micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced muscle-invasive transitional cell carcinoma of the bladder. Cisplatin-based combination chemotherapy enhances survival in patients with metastatic urothelial cancer. Studies evaluating adjuvant chemotherapy have been limited by inadequate statistical power. However, randomized clinical trials have demonstrated a survival benefit for neoadjvuant cisplatin-based combination chemotherapy, which should be considered a standard of care. In addition, neoadjuvant therapy may assist in the rapid development of novel systemic therapy regimens, since pathologic complete remission appears to be a powerful prognostic factor for long-term outcomes. Patients who are either unfit for or refuse radical cystectomy may benefit from neoadjuvant chemotherapy with or without radiation to enable bladder preservation.